Enoximone

SKU: orb1220112

Description

Enoximone is a selective inhibitor of phosphodiesterase III (PDE3), with treatment of congestive heart failure.Perioperative Enoximone administration improved renal function in patients undergoing on-pump cardiac surgery.(In Vitro):In vitro, 10 μM Enoximone-treated bronchoalveolar lavage (BAL) eosinophils induced by IL-33 treatment shows significantly lower CD11b expression when compared with diluent-treated BAL eosinophils.(In Vivo):Topical Enoximone (25 μg; intratracheal route) abrogates house dust mite (HDM)-induced allergic airway inflammation.The Enoximone-treated (25 μg; for 5 days) HDM-exposed mice shows significant reductions in inflammatory cell numbers including eosinophils, macrophages, neutrophils, ILC2s, and T cells, indicating that Enoximone treatment reduces airway inflammation.

Research Area

Pharmacology & Drug Discovery

Key Properties

• CAS Number: 77671-31-9
• MW: 248.3
• Purity: >98% (HPLC)
• Formula: C₁₂H₁₂N₂O₂S
• SMILES: CSc1ccc(cc1)C(=O)c1[nH]c(=O)[nH]c1C
• Target: PDE
• Solubility: In Vitro: DMSO : 8.33 mg/mL (33.55 mM)

Bioactivity

• In Vivo:
  Topical Enoximone (25 μg; intratracheal route) abrogates house dust mite (HDM)-induced allergic airway inflammation. The Enoximone-treated (25 μg; for 5 days) HDM-exposed mice shows significant reductions in inflammatory cell numbers including eosinophils, macrophages, neutrophils, ILC2s, and T cells, indicating that Enoximone treatment reduces airway inflammation.
• In Vitro:
  In vitro, 10 μM Enoximone-treated bronchoalveolar lavage (BAL) eosinophils induced by IL-33 treatment shows significantly lower CD11b expression when compared with diluent-treated BAL eosinophils.

Storage & Handling

• Storage: Storage temperature: -20°C. Stability: ≥ 2 years
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Quick Database Links

Gene Symbol

PDE